Spondyloarthropathies News

WASHINGTON — Among patients with systemic autoimmune rheumatic diseases, circulating interleukin-18 levels were lower in those with long COVID vs. those without, according to data presented at ACR Convergence 2024.

WASHINGTON — Patients with inflammatory arthritis who receive rituximab, interleukin-6 inhibition or Janus kinase inhibitors demonstrate higher severe infection risks vs. TNF inhibitors, according to data presented at ACR Convergence 2024.

WASHINGTON — Withholding Janus kinase or interleukin-17 inhibitors from patients with rheumatoid arthritis or spondyloarthritis does not significantly benefit COVID-19 booster response, according to data presented at ACR Convergence 2024.

Patients with ankylosing spondylitis starting their first TNF inhibitor, and who stayed on said treatment for at least 2 years, demonstrated a median drug survival period of 10.6 years, with 24% discontinuing, according to data.

SAN DIEGO — New imaging technologies, and improved use of the ones currently available, may move rheumatology closer to precision medicine in inflammatory arthritis, according to a speaker at the 2024 Congress of Clinical Rheumatology West.

Smoking, substance use disorder and taking gabapentinoids or antidepressants predict long-term opioid use among patients with axial spondyloarthritis and psoriatic arthritis, according to data published in Rheumatology.

The FDA has expanded the indication of Bimzelx to include psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis with objective signs of inflammation, according to a press release.

Increasing the dosage of secukinumab failed to improve ankylosing spondylitis outcomes among patients who initially demonstrated an inadequate treatment response, according to data published in Rheumatology.

Radiofrequency ablation and transcatheter arterial embolization — both minimally invasive procedures — can improve pain and function in patients with osteoarthritis or chronic sacroiliac pain of degenerative origin, according to data.